Uri Seligsohn
Research Subjects
Research Interests
Uri Seligsohn has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Ariella Zivelin
Institute of Thrombosis and Hemostasis, Departments of Hematology and Internal Medicine, Sheba Medical Center, Tel-Hashomer, Israel
3 shared publicationsNurit Rosenberg
From the Institute of Thrombosis and Hemostasis, Department of Hematology, Israel
3 shared publicationsHava Peretz
From the Institute of Thrombosis and Hemostasis, Department of Hematology, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel; the Department of Laboratory Medicine, University of Vienna, Vienna, Austria; and The Central Laboratory of Hematology, Hotel-Dieu Hospital, Paris, France
2 shared publicationsNurit Kornbrot
From the Institute of Thrombosis and Hemostasis, Department of Hematology, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel; the Department of Laboratory Medicine, University of Vienna, Vienna, Austria; and The Central Laboratory of Hematology, Hotel-Dieu Hospital, Paris, France
2 shared publicationsSanford Gitel
From the Institute of Thrombosis and Hemostasis, Departments of Hematology and Internal Medicine, Sheba Medical Center, Tel-Hashomer, Israel; and the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA
2 shared publicationsAharon Lubetsky
1 shared publication
Latest Publications
- Open Access
- 30 April 2004
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (7) , 1167-1175
A novel Phe171Cys mutation in integrin αIIb causes Glanzmann thrombasthenia by abrogating αIIbβ3 complex formation
- 30 April 2004
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (7) , 1167-1175
Open AccessA novel Phe171Cys mutation in integrin αIIb causes Glanzmann thrombasthenia by abrogating αIIbβ3 complex formation
- Top Cited Papers
- 19 April 2001
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (16) , 1222-1231
Genetic Susceptibility to Venous Thrombosis
The annual incidence of venous thrombosis, one of the leading causes of mortality and morbidity, increases from 1 per 100,000 during childhood to 1 per 100 in old age.1 In this article we will discuss conditions involving a genetic predisposition to venous thrombosis. The clinical relevance of this topic has increased with new evidence of the high prevalence of mutant genes that increase susceptibility to thrombosis.Of the three mechanisms of thrombosis defined by Virchow in the 19th century — vessel-wall injury, stasis, and “changes in the composition of blood” (hypercoagulability) — the last two predominate in venous thrombosis. Hypercoagulability . . .
- 19 April 2001
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (16) , 1222-1231
Top Cited PapersGenetic Susceptibility to Venous Thrombosis
The annual incidence of venous thrombosis, one of the leading causes of mortality and morbidity, increases from 1 per 100,000 during childhood to 1 per 100 in old age.1 In this article we will discuss conditions involving a genetic predisposition to venous thrombosis. The clinical relevance of this topic has increased with new evidence of the high prevalence of mutant genes that increase susceptibility to thrombosis.Of the three mechanisms of thrombosis defined by Virchow in the 19th century — vessel-wall injury, stasis, and “changes in the composition of blood” (hypercoagulability) — the last two predominate in venous thrombosis. Hypercoagulability . . .
- Open Access
- 1 August 1999
- Published by American Society of Hematology in Blood
- Vol. 94 (3) , 895-901
Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C
Activated protein C resistance (APCR) in the absence of alterations in the factor V gene has been observed during pregnancy, in patients on oral contraceptives, in the presence of antiphospholipid antibodies, and in patients with ischemic stroke. We report a 49-year-old woman with recurrent major venous and arterial thromboses who displayed pronounced APCR, yet no changes in the activated protein C (APC) cleavage sites of factor V. The APCR values determined by four different assays were similar to those obtained in plasma from a homozygote for factor V Q506. Addition of IgG isolated from the patient’s serum to normal plasma lowered the APCR ratio from 2.4 to 1.6. Incubation of patient’s IgG with normal APC resulted in a profound change in the mobility of APC in crossed immunoelectrophoresis. APC was also shown to bind to patient’s IgG immobilized on a protein A agarose column. Factor Va inactivation by APC was inhibited by patient’s IgG, but not by control IgG in the presence or absence of either phospholipids or protein S. These results provide evidence for the existence of an acquired antibody against APC in the patient’s plasma, which gave rise to the APCR phenotype and was probably responsible for the major thrombotic events. We suggest that acquired APCR due to anti-APC antibodies be considered a potential cause for severe venous and arterial thromboses.
- 1 August 1999
- Published by American Society of Hematology in Blood
- Vol. 94 (3) , 895-901
Open AccessExtensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C
Activated protein C resistance (APCR) in the absence of alterations in the factor V gene has been observed during pregnancy, in patients on oral contraceptives, in the presence of antiphospholipid antibodies, and in patients with ischemic stroke. We report a 49-year-old woman with recurrent major venous and arterial thromboses who displayed pronounced APCR, yet no changes in the activated protein C (APC) cleavage sites of factor V. The APCR values determined by four different assays were similar to those obtained in plasma from a homozygote for factor V Q506. Addition of IgG isolated from the patient’s serum to normal plasma lowered the APCR ratio from 2.4 to 1.6. Incubation of patient’s IgG with normal APC resulted in a profound change in the mobility of APC in crossed immunoelectrophoresis. APC was also shown to bind to patient’s IgG immobilized on a protein A agarose column. Factor Va inactivation by APC was inhibited by patient’s IgG, but not by control IgG in the presence or absence of either phospholipids or protein S. These results provide evidence for the existence of an acquired antibody against APC in the patient’s plasma, which gave rise to the APCR phenotype and was probably responsible for the major thrombotic events. We suggest that acquired APCR due to anti-APC antibodies be considered a potential cause for severe venous and arterial thromboses.
- 1 January 1999
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 82 (09) , 1015-1019
Risk Factors Associated with Postpartum Ovarian Vein Thrombosis
Summary: Thrombosis of the ovarian vein is a remarkable process occuring within a few days of labor in 1:500-1:2000 women. Its presentation is characterized by fever, abdominal pain and occasionally by a palpable abdominal mass that in earlier years sometimes lead to explorative laparotomy. With the advent of modern imaging techniques the diagnosis can be made relatively easily. The pathogenesis has been attributed to an infectious process expanding from the uterus to the right ovarian vein and stasis. A predisposition towards thrombosis has not been so far explored. In this study we retrospectively analysed the clinical features, diagnosis and treatment of 22 patients with objective documentation of post partum ovarian vein thrombosis (POVT) and assessed potential risk factors. In 11 of the 22 patients (50%) inherited prothrombotic risk factors were detected as follows: 4 were heterozygous for factor V G1691 A, 2 had protein S deficiency, one had protein S deficiency and was heterozygous for factor V G1691A, and 4 were homozygous for MTHFR C677T. Eight of the 11 patients who bore a prothrombotic predisposition underwent cesarean section. Taken together, the data suggest that POVT may result from the combined effect of an infection, cesarean section and a prothrombotic tendency.
- 1 January 1999
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 82 (09) , 1015-1019
Risk Factors Associated with Postpartum Ovarian Vein Thrombosis
Summary: Thrombosis of the ovarian vein is a remarkable process occuring within a few days of labor in 1:500-1:2000 women. Its presentation is characterized by fever, abdominal pain and occasionally by a palpable abdominal mass that in earlier years sometimes lead to explorative laparotomy. With the advent of modern imaging techniques the diagnosis can be made relatively easily. The pathogenesis has been attributed to an infectious process expanding from the uterus to the right ovarian vein and stasis. A predisposition towards thrombosis has not been so far explored. In this study we retrospectively analysed the clinical features, diagnosis and treatment of 22 patients with objective documentation of post partum ovarian vein thrombosis (POVT) and assessed potential risk factors. In 11 of the 22 patients (50%) inherited prothrombotic risk factors were detected as follows: 4 were heterozygous for factor V G1691 A, 2 had protein S deficiency, one had protein S deficiency and was heterozygous for factor V G1691A, and 4 were homozygous for MTHFR C677T. Eight of the 11 patients who bore a prothrombotic predisposition underwent cesarean section. Taken together, the data suggest that POVT may result from the combined effect of an infection, cesarean section and a prothrombotic tendency.
- Open Access
- 15 August 1998
- Published by American Society of Hematology in Blood
- Vol. 92 (4) , 1119-1124
A Single Genetic Origin for the Common Prothrombotic G20210A Polymorphism in the Prothrombin Gene
The polymorphism G20210A in the 3′ untranslated region of the prothrombin gene is associated with an increased level of factor II activity and confers a twofold to fivefold increase in the risk for venous thromboembolism. Among Caucasian populations, the prevalence of factor II G20210A heterozygotes is 1% to 6%, whereas in non-Caucasian populations it is very rare or absent. The aim of the present study was to discern whether factor II G20210A originated from a single or recurrent mutational events. Allele frequencies of four dimorphisms spanning 16 of 21 kb of the factor II gene were determined in 133 unrelated Caucasian subjects of Jewish, Austrian, and French origins who bore factor II G20210A (10 homozygotes and 123 heterozygotes) and 110 Caucasian controls. Remarkable differences in the allele frequencies for each dimorphism were observed between the study groups (P = .0007 or less), indicating strong linkage disequilibrium and suggesting a founder effect. Indeed, a founder haplotype was present in 68% of 20210A mutant alleles and only in 34% of 20210G normal alleles (P < .0001). These data strongly support a single origin for factor II G20210A that probably occurred after the divergence of Africans from non-Africans and of Caucasoid from Mongoloid subpopulations. © 1998 by The American Society of Hematology.
- 15 August 1998
- Published by American Society of Hematology in Blood
- Vol. 92 (4) , 1119-1124
Open AccessA Single Genetic Origin for the Common Prothrombotic G20210A Polymorphism in the Prothrombin Gene
The polymorphism G20210A in the 3′ untranslated region of the prothrombin gene is associated with an increased level of factor II activity and confers a twofold to fivefold increase in the risk for venous thromboembolism. Among Caucasian populations, the prevalence of factor II G20210A heterozygotes is 1% to 6%, whereas in non-Caucasian populations it is very rare or absent. The aim of the present study was to discern whether factor II G20210A originated from a single or recurrent mutational events. Allele frequencies of four dimorphisms spanning 16 of 21 kb of the factor II gene were determined in 133 unrelated Caucasian subjects of Jewish, Austrian, and French origins who bore factor II G20210A (10 homozygotes and 123 heterozygotes) and 110 Caucasian controls. Remarkable differences in the allele frequencies for each dimorphism were observed between the study groups (P = .0007 or less), indicating strong linkage disequilibrium and suggesting a founder effect. Indeed, a founder haplotype was present in 68% of 20210A mutant alleles and only in 34% of 20210G normal alleles (P < .0001). These data strongly support a single origin for factor II G20210A that probably occurred after the divergence of Africans from non-Africans and of Caucasoid from Mongoloid subpopulations. © 1998 by The American Society of Hematology.
- Open Access
- 1 September 1997
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 43 (9) , 1657-1659
Improved Method for Genotyping Apolipoprotein E Polymorphisms by a PCR-Based Assay Simultaneously Utilizing Two Distinct Restriction Enzymes
Apolipoprotein E (apo E) is a protein that plays an essential role in lipid metabolism and distribution (1). The apo E gene is polymorphic, and its three alleles code for isoforms E2, E3, and E4, which differ by single-amino-acid substitutions (2). The apo E3 allele is the predominant isoform in all populations studied. The apo E4 allele is associated with increased total serum cholesterol and greater odds for coronary heart disease (3); it also constitutes a major risk factor for Alzheimer disease (4). The apo E2 allele seems to have a protective effect against Alzheimer disease and is associated with longevity (5). Consequently, interest in examining individual patients and study groups for the apo E isoforms is growing. In this communication we describe a simple procedure that facilitates the genotyping of the apo E polymorphisms.
- 1 September 1997
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 43 (9) , 1657-1659
Open AccessImproved Method for Genotyping Apolipoprotein E Polymorphisms by a PCR-Based Assay Simultaneously Utilizing Two Distinct Restriction Enzymes
Apolipoprotein E (apo E) is a protein that plays an essential role in lipid metabolism and distribution (1). The apo E gene is polymorphic, and its three alleles code for isoforms E2, E3, and E4, which differ by single-amino-acid substitutions (2). The apo E3 allele is the predominant isoform in all populations studied. The apo E4 allele is associated with increased total serum cholesterol and greater odds for coronary heart disease (3); it also constitutes a major risk factor for Alzheimer disease (4). The apo E2 allele seems to have a protective effect against Alzheimer disease and is associated with longevity (5). Consequently, interest in examining individual patients and study groups for the apo E isoforms is growing. In this communication we describe a simple procedure that facilitates the genotyping of the apo E polymorphisms.